View Older Stories View More Recent Stories
-
Leerink starts coverage on Boston Scientific and Medtronic with bullish ratings
-
Leerink Partners Starts Abbott Labs (ABT) at Market Perform
-
Abbott (ABT) Declares $0.59 Quarterly Dividend; 1.7% Yield
-
Piper Sandler Highlights Top Medtech Picks and Catalyst-Rich Names
-
Tandem Diabetes (TNDM) partners with Abbott (ABT) for integration
-
Evercore ISI on Boston Scientific (BSX) Read-through: 'This should be a positive for ABT & MDT'
-
JPMorgan on Boston Scientific (BSX): 'We’d be buyers of BSX on any material weakness'
-
Abbott (ABT) Receives FDA Approval for Tendyne
-
Abbott's (ABT) Libre Technology is First Continuous Glucose Monitor Associated with Reduced Hospitalizations for Heart Complications in People with Diabetes
-
These 2 sectors are under-owned, Barclays says and advises where to invest
-
Abbott (ABT) Active, Shares Up 4%
-
Medtech Q1 earnings preview: Potential tariff exposure
-
Abbott Labs (ABT) PT Raised to $144 at Bernstein SocGen Group
-
Abbott Labs (ABT) PT Raised to $145 at TD Cowen
-
Abbott Labs (ABT) PT Raised to $145 at RBC Capital, Citing 'Positive Business Fundamentals'
-
UBS Reiterates Buy Rating on Abbott Labs (ABT)
-
Abbott Labs (ABT) PT Raised to $145 at Piper Sandler on "Organic Growth'
-
Abbott Labs (ABT) PT Raised to $145 at Stifel
-
Abbott Labs (ABT) PT Raised to $140 at Oppenheimer
-
Abbott Labs (ABT) PT Raised to $142 at Raymond James
-
Abbott Labs (ABT) PT Raised to $145 at BTIG
-
Abbott Labs (ABT) PT Raised to $137 at Jefferies
-
Abbott Labs (ABT) PT Raised to $140 at Evercore ISI
-
Stifel Reiterates Buy Rating on Abbott Labs (ABT)
-
BTIG Reiterates Buy Rating on Abbott Labs (ABT)
-
Mizuho Reiterates Neutral Rating on Abbott Labs (ABT)
-
JPMorgan Reiterates Overweight Rating on Abbott Labs (ABT)
-
Abbott (ABT) Tops Q1 EPS by 2c, Offers Guidance
-
Abbott (ABT) call put ratio 1.1 calls to 1 put into quarter results
-
Abbott (ABT) call put ratio 2.8 calls to 1 put into quarter results
-
Stifel Reiterates Buy Rating on Abbott Labs (ABT)
-
TD Cowen Reiterates Buy Rating on Abbott Labs (ABT), Expecting 'Good Quarterly Results'
-
Oppenheimer Reiterates Outperform Rating on Abbott Labs (ABT)
-
Piper Sandler Conducts a Survey: 'Abbott Labs (ABT) Biggest Share Gainer'
-
RBC Capital Assesses U.S. Tariff Impact Across Industries
-
Oppenheimer Reiterates Outperform Rating on Abbott Labs (ABT) Following CE Mark news
-
BTIG Reiterates Buy Rating on Abbott Labs (ABT)
-
Abbott (ABT) Receives CE Mark for its Volt Pulsed Field Ablation System to Treat Patients with Abnormal Heart Rhythms
-
Abbott (ABT) initiates new trail for Coronary IVL System
-
TD Cowen Reiterates Buy Rating on Abbott Labs (ABT)
-
Abbott (ABT) call put ratio 1.2 calls to 1 put amid price movement
-
RFK Jr. Said To Meet With Baby Formula Manufacturers - Bloomberg
-
BofA Securities on Abbott Labs (ABT): 'durable revenue growth at the high end of medtech and double-digit EPS growth'
-
Citi on Abbott Labs (ABT): 'we view the overturned state case as incrementally negative'
-
RBC Capital: 'Opportunities Across MedTech Stocks'
-
Jefferies Reiterates Hold Rating on Edwards Lifesciences (EW)
-
Cadrenal Therapeutics (CVKD) Announces Collaboration Agreement with Abbott (ABT) in Support of Pivotal Study of Tecarfarin in Patients with HeartMate 3 LVAD
-
Abbott (ABT) Declares $0.59 Quarterly Dividend; 1.8% Yield
-
IVF stocks on watch as President Trump signs an executive order to expand access
-
KeyBanc Highlights WST, GXIG, and STVN as GLP-1 Estimates Raise

